FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
Study sponsor: Bicara Therapeutics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2028-04Estimated
Enrollment · participants650Estimated
Source updated2026-11-19Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.